Role of Radiation and Androgen Deprivation Therapy for Advanced Prostate Cancer
In the sections that follow further detail will be provided on (a) the addition of hormone therapy to radiotherapy and vice versa, (b) the duration and timing of hormone therapy, and (c) ongoing investigations in this active study area. Note that the discussion will be limited to the use of ADT with XRT in the locally advanced intact prostate cancer (ie, not post-prostatectomy) setting. Note also that the discussion of radiotherapy will be restricted to external beam radiotherapy (EBRT) as opposed to brachytherapy, as EBRT is the primary clinical setting in which combination ADT and XRT has been investigated. (Source: Curr...
Source: Current Problems in Cancer - November 25, 2014 Category: Cancer & Oncology Authors: Ashesh B. Jani, Peter J. Rossi Source Type: research
Role of Brachytherapy for Advanced Prostate Cancer
Brachytherapy, or the technique of placing radioactive material inside or next to an area of cancer, has a long history in the treatment of advanced prostate cancer. As early as 100 years ago urologists were using brachytherapy for the treatment of advanced prostate cancer in the United States and Europe1. HH Young, a John Hopkins surgeon and the father of many modern urology techniques developed an interstitial brachytherapy technique for placement of radiotherapy isotopes inside the prostate to treat cancer1. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 25, 2014 Category: Cancer & Oncology Authors: Peter J. Rossi Source Type: research
Update on Systemic Therapy for Advance Prostate Cancer
In 1942 Huggins and Hodges published data establishing the role of androgens in prostate cancer by showing that inhibition of androgens lead to regression of advanced prostate cancer 1. Androgen deprivation remains the mainstay of treatment for metastatic prostate cancer or situations that are not amenable to local therapy. Androgen deprivation or castration takes place either by medical or surgical means. Clinically this is demonstrated by a testosterone level < 50ng/ml. Surgical castration is an efficient way to abruptly remove the source of androgens 2 and is a viable option for some men. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 25, 2014 Category: Cancer & Oncology Authors: Bradley Carthon, Peter J. Rossi Source Type: research
Introduction
Prostate cancer remains a significant problem in the United States. There are 233,000 cases predicted to occur in 2014, and nearly 30,000 men in the United States are projected to die owing to this disease.1 Despite successful local interventions, which are reviewed in this issue, many men will develop progressive disease requiring further therapies and often succumb to disease. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 24, 2014 Category: Cancer & Oncology Authors: Peter J. Rossi Source Type: research
Introduction: Current Problems in Cancer
Prostate cancer remains a significant problem in the United States. There are 233,000 cases predicted to occur in 2014 and nearly 30,000 men in the United States are projected to die from this disease 1. Despite successful local interventions that will be reviewed in this article, many men will develop progressive disease requiring further therapies and often succumb to disease. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 24, 2014 Category: Cancer & Oncology Authors: Peter J. Rossi Source Type: research
Foreword
This is one of our most unique issues, and to be honest, quite possibly one of our most practical. In the following monograph, Dr. Bellcross and her colleagues cover the gamut of inherited genetic syndromes in a unique case-based format. The information included in this edition is exceptionally useful and extremely timely. While hereditary breast and ovarian cancer has recently drawn considerable national attention, particularly given the celebrity status it has achieved, the other inherited syndromes have equal importance and significance. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 5, 2014 Category: Cancer & Oncology Authors: Keith A. Delman Source Type: research
Title Page
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 1, 2014 Category: Cancer & Oncology Source Type: research
Table of Contents
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 1, 2014 Category: Cancer & Oncology Source Type: research
Author BioSketches
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 1, 2014 Category: Cancer & Oncology Source Type: research
Hereditary breast and ovarian Cancer syndrome: Considering the Complexities
Hereditary Breast and Ovarian Cancer syndrome (HBOC) is a well-described hereditary cancer predisposition syndrome caused by mutations in BRCA1 and BRCA2. Several studies have provided lifetime breast cancer risk estimates for women with HBOC, and most have suggested a risk between 50 and 80%.1 Men with BRCA mutations have a risk of up to 8% of developing breast cancer in their lifetimes.2 In females, the risk of developing breast cancer appears to be slightly higher in carriers of BRCA1 mutations compared to carriers of BRCA2 mutations, while the opposite is true with regard to the risks for male breast cancer. (Source: C...
Source: Current Problems in Cancer - October 31, 2014 Category: Cancer & Oncology Authors: Leigha Senter Source Type: research
Beyond and
Hereditary breast and ovarian cancer (HBOC) syndrome associated with mutations in the BRCA1 or 2 genes, comprises the largest single portion of known hereditary breast cancer syndromes. However, there are several other, less common hereditary cancer syndromes that also include a substantially increased risk for breast cancer. When evaluating a family for possible genetic testing, it is important to ensure that all appropriate syndromes are considered. Identifying the correct hereditary breast cancer syndrome can have significant impact on quality and length of life for the patient and their relatives. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - October 31, 2014 Category: Cancer & Oncology Authors: Kimberly King-Spohn, Robert Pilarski Source Type: research
Hereditary colorectal cancer: More common than you think
It is estimated that over 20% of all colorectal cancers (CRCs) have a familial component, and up to 6% of cases are due to a known high-risk hereditary syndrome.1 It is imperative that healthcare providers keep abreast of the genetics of CRC, as one in five CRC patients walking through their office door may need referral for genetic counseling. Despite the well-documented benefits of increased screening and risk reducing interventions in hereditary CRC syndromes, many remain undiagnosed. Reviewed here are novel and proven strategies to identify patients at risk for hereditary CRC syndromes, with a focus on Lynch syndrome (...
Source: Current Problems in Cancer - October 31, 2014 Category: Cancer & Oncology Authors: Kory Jasperson Source Type: research
The Genetics of Endocrine Neoplasia
The hereditary endocrine neoplasias are a group of inherited disorders in which both benign and malignant tumors of various endocrine tissues occur at a relatively high frequency. Endocrine neoplasias can occur outside of the context of a hereditary cancer syndrome and range in incidence from quite common (e.g. parathyroid adenomas) to quite rare (e.g. pancreatic insulinoma). Hereditary endocrine neoplasias are characterized by the development of benign or malignant tumors in more than one endocrine tissue, multi-focal and/or bilateral tumors, and have an earlier age of onset than their sporadic counterparts. (Source: Curr...
Source: Current Problems in Cancer - October 31, 2014 Category: Cancer & Oncology Authors: Rebecca Nagy Source Type: research
The changing landscape of genetic testing for hereditary breast and ovarian cancer
It took Angelina Jolie’s announcement in 2013 to bring broad awareness of hereditary breast and ovarian cancer (HBOC) to the general public. However, it has been 25 years since Mary-Claire King mapped BRCA1 to chromosome 17 through linkage analysis involving painstaking collection of a large number of families with multiple cases of early-onset breast cancer.1 Though familial “clusters” of breast cancer had been described since the early 1800s, the concept that cancer can result from inheritance of a single faulty gene first made its way into the scientific literature when Knudson2 published his famous “2-hit hypot...
Source: Current Problems in Cancer - October 30, 2014 Category: Cancer & Oncology Authors: Cecelia A. Bellcross Source Type: research
The Changing Landscape of Genetic Testing for Hereditary Breast/Ovarian Cancer
It took Angelina Jolie’s announcement in 2013 to bring broad awareness of hereditary breast/ovarian cancer (HBOC) to the general public. However, it has been 25 years since Mary-Claire King mapped BRCA1 to chromosome 17 through linkage analysis involving painstaking collection of a large number of families with multiple cases of early-onset breast cancer.1 Though familial “clusters” of breast cancer had been described since the early -1800’s, the concept that cancer can result from inheritance of a single faulty gene first made its way into the scientific literature when Knudson published his famous “two-hit hypo...
Source: Current Problems in Cancer - October 30, 2014 Category: Cancer & Oncology Authors: Cecelia Bellcross Source Type: research
